## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.9% below STRENGTH zone (4.0-10.0%); PEG 1.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Hologic stock hits 52-week high at $75.14 By Investing.com**
- Source: Investing.com Australia | 20251215T150019 | Bullish | Relevance: 100%
- Hologic Inc (HOLX) stock recently hit a 52-week high of $75.14, marking a 3.67% increase over the past year. The medical technology company demonstrates strong financial health with moderate debt, an impressive Altman Z-Score, and low price volatility, trading slightly below its Fair Value according to InvestingPro. Recent news also highlights strong Q4 2025 results, expanded CE marking for its Genius Digital Diagnostics System in the EU, and upcoming presentations on its Breast Cancer Index Test.

**2. Hologic's BCI test shows growing impact in endocrine therapy decisions**
- Source: MSN | 20251214T091945 | Bullish | Relevance: 100%
- The article highlights the increasing influence of Hologic's Breast Cancer Index (BCI) test on endocrine therapy decisions. This suggests that the BCI test is gaining recognition as a valuable tool for guiding treatment strategies in breast cancer patients.

**3. Hologic stock hits 52-week high at $75.14 By Investing.com**
- Source: Investing.com Nigeria | 20251215T150804 | Bullish | Relevance: 100%
- Hologic Inc. (HOLX) stock recently reached a 52-week high of $75.14, demonstrating the medical technology company's positive trend and a 3.67% increase over the past year. This milestone is supported by strategic initiatives, product innovations, aggressive share buybacks, and strong financial health indicated by an Altman Z-Score of 5.79. Recent positive news for the company includes strong fiscal Q4 2025 results, an expanded CE marking for its Genius Digital Diagnostics System, and upcoming presentations on its Breast Cancer Index Test.

**4. InMode’s Shares Look Cheap—But Caution Remains For 2025**
- Source: Finimize | 20251215T080843 | Neutral | Relevance: 61%
- InMode (NASDAQ: INMD) stock appears undervalued with strong fundamentals, including robust gross margins and a substantial net cash position, despite a recent 13.1% decline over the past year. However, revised lower revenue guidance for 2025 and weaker demand for aesthetic treatments in North America introduce caution for near-term investors. Growth opportunities lie in international expansion and new product launches, but competition and economic sensitivity pose risks.

**5. BBR Partners LLC Sells 35,000 Shares of GRAIL, Inc. $GRAL**
- Source: MarketBeat | 20251213T100833 | Neutral | Relevance: 55%
- BBR Partners LLC significantly reduced its stake in GRAIL, Inc. (NASDAQ:GRAL) by 77.8%, selling 35,000 shares and ending Q2 with 10,001 shares valued at $514,000. Insider selling has also been substantial, with CEO Robert Ragusa and President Joshua Ofman selling a combined 13,353 shares, contributing to a total of 113,295 insider shares worth $7.38 million sold in the past 90 days. Despite mixed analyst ratings, with some upgrades and higher price targets, the stock holds a consensus "Hold" rating with an average price target of $97.50.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.27M) |
| Sells | 25 ($6.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.66 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.5x). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.8B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.66 |
| Forward P/E | 15.1 |
| Current P/E | 16.5 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.8% to 0.9% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: +MUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.86% (CS: 42) | Neutral |
| RSI_14 | 69.4 | Neutral |
| MACD Histogram | -0.12 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.030x | Above |
| vs SMA200 | 1.146x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $75.19
- **Stop Loss:** $74.45 (1.0% risk)
- **Target:** $75.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1621
- **Position Value:** $121,882.99
- **Portfolio %:** 121.88%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*